CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Insulin aspart/insulin aspart protamine

Last Updated: October 13, 2005
Result type: Reports
Project Number: SR0041-000
Product Line: Reimbursement Review

Generic Name: Insulin aspart/insulin aspart protamine

Brand Name: NovoMix 30

Manufacturer: Novo Nordisk Canada Inc.

Therapeutic Area: Diabetes mellitus

Indications: Diabetes mellitus

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 26, 2006

Recommendation Type: Do not list